dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
MYDAYIS is an extended-release oral capsule combining four amphetamine salts (dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate) approved in 2017. It is indicated for attention-deficit/hyperactivity disorder (ADHD) and works by stimulating central nervous system activity to improve focus, attention, and impulse control. The extended-release formulation provides once-daily dosing with a unique biphasic release profile designed for sustained symptom management throughout the day.
With LOE approaching in 2.9 years and modest Medicare spending ($3M in 2023), the brand team is likely consolidating and planning for generic transition; limited growth opportunity remains.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
LOE in ~3 years — strategic planning for patent cliff underway
Worked on MYDAYIS at Takeda? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
With zero linked jobs and LOE approaching in 2.9 years, MYDAYIS offers limited near-term career growth; roles focus on defending market share and managing generic transition. Professionals seeking dynamic brand-building or clinical expansion should consider other products, though market access and price optimization experience is valuable.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo